FDA Grants Approval for Calcium Gluconate by Caplin
The FDA has granted approval for Calcium Gluconate under application ANDA218840 submitted by Caplin.
Published: August 3, 2026
Updated: August 3, 2026
Author: Humanexa Intelligence
Therapeutic area: Electrolyte Imbalance / Calcium Supplement
Asset: Caplin
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Caplin
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Calcium Gluconate by Caplin marks a significant regulatory milestone that could reshape the competitive landscape in the electrolyte supplement market. Portfolio teams must evaluate the implications for market share and pricing strategies as Caplin enters the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market response and Caplin's launch strategy for Calcium Gluconate.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.